Repros Therapeutics

Repros Therapeutics — Investor Presentation (September 2016)

26 slides from Repros Therapeutics's investor presentation, Sep 12, 2016

  1. Slide 1: Repros Therapeutics

    Repros Therapeutics Development of small molecule drugs for major unmet medical needs that treat male and female reproductive disorders.

  2. Slide 2: Repros Disclaimer

    Repros Disclaimer Any statements made by Repros Therapeutics Inc . (“Repros” or the “Company”) that are not historical facts contained in these slides (or in any oral accompanying discussion) are forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995

  3. Slide 3: Proellex: Addressing significant unmet female reproductive disorders

    Proellex Addressing significant unmet female reproductive disorders

  4. Slide 4: Uterine Fibroids & Endometriosis

    Uterine Fibroids & Endometriosis Poor therapeutic options for debilitating female disorders experienced by women in the prime of their life • Benign, monoclonal, hormone sensitive, smooth muscle tumors of the uterus • Most common tumor of the female reproductive tract – Heavy bleeding / anemia – Abd

  5. Slide 5: How Antiprogestins Like Proellex Work

    O O OMe N OAc CH 3 H 3 C How Antiprogestins Like Proellex Work Antiprogestins • Selectively block progesterone activity • Allow tonic hormone secretions – Alleviate negative side effects of GnRHa • Potential for chronic use Different than GnRH agonists and antagonists. These agents: • Block hypothal

  6. Slide 6: Proellex Evolution of Lead Compound

    PROELLEX EVOLUTION OF LEAD COMPOUND O CH 3 O OMe N OAc CH 3 H 3 C 44 Analogues Synthesized to Date O CH 3 OH 3 C N OAc CH 3 H 3 C CDB - 2914 ( Ulipristal Acetate) • NIH precursor to Repros class • Allergan marketing molecule ( Esmya ) in Europe for treatment of uterine fibroids CDB - 4124 Proellex (

  7. Slide 7: An Effective Dose of Proellex Stops Menstruation in Majority of Women

    An Effective Dose of Proellex Stops Menstruation in Majority of Women Induction of amenorrhea relieves key symptoms of uterine fibroids and endometriosis 0 10 20 30 40 50 60 70 80 90 100 1 mg 3 mg 6 mg 9 mg 12 mg 25 mg 50 mg % of Women with Induced Amenorrhea Proellex induced amenorrhea (no ovulatio

  8. Slide 8: Impact of Proellex Treatment on Uterine Fibroids

    Impact of Proellex Treatment on Uterine Fibroids -60 -40 -20 0 20 40 60 80 100 % Amenorrhea % Reduction in Fibroid Volume % Effects of 12 mg Proellex after 18 weeks of continuous treatment of severe uterine fibroids (menstrual blood loss > 80mL/ cycle) LOCF Analysis 12 mg Proellex Placebo Fibroids c

  9. Slide 9: Impact of Proellex Treatment on Endometriosis

    Impact of Proellex Treatment on Endometriosis 0 2 4 6 8 10 12 14 Baseline End of 18 Wk Off Drug Interval Median Sum of BBSS Scored Menstrual Pain Over 28 Day Cycle Proellex Placebo p=0.0013 N=43 Proellex , 17 Placebo 47 in US, 13 in Argentina BBSS Classification Moderate to Severe

  10. Slide 10: Impact of Proellex Treatment on Endometriosis

    Impact of Proellex Treatment on Endometriosis -70 -60 -50 -40 -30 -20 -10 0 4 Wk 8 Wk 12 Wk 18 Wk LOCF Off Drug Interval Median % Change in Non - Prescription Analgesics Proellex Placebo p=0.0093 -100 -90 -80 -70 -60 -50 -40 -30 -20 -10 0 4 Wk 8 Wk 12 Wk 18 Wk LOCF Off Drug Interval Median % Change

  11. Slide 11: Key Advantage of Proellex Over Other Antiprogestins in Development

    All other antiprogestins in development require off - drug - interval after 12 weeks of treatment Key Advantage of Proellex Over Other Antiprogestins in Development Proliferative Disordered Proliferative Benign Endometrial Hyperplasia Mutter et al, 2007 12.5mg Proellex No hyperplasia Estrogen over T

  12. Slide 12: Proellex Clinical Goals

    Proellex Clinical Goals • Confirm Phase 3 requirements with FDA • Uterine Fibroids: Request Mtg. Q4 - ’16 • Endometriosis : Request Mtg. Q4 - ’16 • Completed Proellex NDA components • Pre - clinical complete (including 2 carcinogenicity studies) • Manufacturing complete (API sourced, stable final dr

  13. Slide 13: Proellex Summary

    Proellex Summary • Potential Proellex market opportunity > $1 Billion for Fibroids and Endometriosis • Rigorous clinical program working to move into Phase 3 • Significant clinical advantages identified against GnRH agonists/antagonists • Longer symptom relief established against other approved or i

  14. Slide 14: Encyzix (enclomiphene): Rational treatment for secondary hypogonadism

    Encyzix ( enclomiphene ) Rational treatment for secondary hypogonadism

  15. Slide 15: Enclomiphene Development Status

    Enclomiphene Development Status • Central EU filing ongoing – Anticipated marketing authorization Q4 - ’17 – Treatment for secondary hypogonadism • FDA Complete Response to NDA – We expect FDA to hold advisory committee meeting on secondary hypogonadism to discuss need for treatment that preserves t

  16. Slide 16: Prescription Claims for Testosterone Products

    CM - 16 Prescription Claims for Testosterone Products Nguyen et al N Eng J Med 2015 73% 9% 3%

  17. Slide 17: Prevalence of Overweight and Obesity

    CM - 17 Prevalence of Overweight and Obesity Global Burden of Disease Study 2013 (Ng et al Lancet 2014) Prevalence (%) 70 60 50 40 3 0 20 10 0 2 - 9 10 - 19 20 - 29 30 - 39 40 - 49 50 - 59 60 - 69 70 - 79 ≥80 Age (years) 29.0 39.4 32.0 0 20 40 60 20-39 Years 40-59 Years ≥60 Years Percent CDC (Ogden,

  18. Slide 18: Secondary Hypogonadism: The Leading Cause of Low T

    Secondary Hypogonadism The Leading Cause of Low T and Usage of T Replacement Therapies It is not age related! The vast majority of hypogonadal men are secondary and suffer from the disorder due to being overweight or obese EMAS data suggests the incidence of secondary hypogonadism is nearly 10X grea

  19. Slide 19: Secondary Hypogonadism at Baseline

    Institute of Human Development Centre for Endocrinology & Diabetes Manchester Academic Health Sciences Centre Secondary Hypogonadism at Baseline Age (years) BMI ≥ 25 - <30 kg/m2 BMI ≥ 30 kg/m2 Smoking (current) Alcohol (frequent) Morbidity ( ≥ 1) 0 5 10 15 *** *** * Poor morning erection Sexual thou

  20. Slide 20: Phase 2 Proof of Concept Diet & Exercise Study in Obese Hypogonadal Men

    Phase 2 Proof of Concept “Diet & Exercise” Study in Obese Hypogonadal Men - Baseline Findings Screen 98 to enroll 50 15 Month Study • Enrollment (n=50 in 5 weeks @ 5 sites) • Demographics ( stdev ) – Age: 43.3 (9.2) – BMI: 36.8 (3.2) – Waist: 46.9” (4.1) – % Body Fat: 38.1 (5.2) • Hormonal Status –

  21. Slide 21: How Enclomiphene Works

    How Enclomiphene Works Enclomiphene blocks estrogen at the level of the H - P axis increasing LH levels which in turn increases endogenous production of T 0 1 2 3 4 5 6 7 Enclomiphene LH Androgel LH Median LH ( mIU /mL) Impact on LH in 16 Wk Study ZA - 304 Baseline End of Study 0 50 100 150 200 250

  22. Slide 22: Interim Month Data (CLEIA assay)

    Interim 6 Month Data (CLEIA assay) ZA - 205 30 31 32 33 34 35 36 37 38 39 Bl 3 mo 6 mo 9 mo 12 mo 15mo BMI BMI Over Time 12.5 mg 25 mg pbo 0 100 200 300 400 500 600 700 Scr BL 3 mo 6 mo 9 mo 12 mo 15 mo Morning T (ng/ dL ) Morning T Over Time 12.5 mg 25 mg pbo Commercial diet ends at 6 months. Perso

  23. Slide 23: Interim Month Data: Lean Mass, LCMS T & Free T

    Interim 6 Month Data Lean Mass, LCMS T & Free T 63.5 64 64.5 65 65.5 66 66.5 67 67.5 68 68.5 Baseline 6 Month 12 Month 15 Month Lean Mass by DXA (kg) 12.5 mg 25 mg Placebo 0 20 40 60 80 100 120 140 160 180 0 100 200 300 400 500 600 700 800 900 1000 Baseline 6 Month 12 Month 15 Month Free T ( pg /mL)

  24. Slide 24: Size of Overweight and Obese US Population

    Size of Overweight and Obese US Population It is more than a sex issue 83,740,000 Males Age 20 - 60 58,620,000 Overweight or Obese 28,470,000 Metabolic Syndrome 1,700,000 Symptomatic (libido, etc.) Overweight or Obese Estimates based on CDC, EMAS and Sponsor Data

  25. Slide 25: Repros Late Stage Assets

    Repros Late Stage Assets Repros seeking regional or global development/commercialization partners

  26. Slide 26: Financial Summary

    Financial Summary • Cash and equivalents: (unaudited June 30, 2016) $12.5 M • Cash used in 2016 through June 30, 2016 : $8.9 M • Cash runway: Q1 2017 • Current shares outstanding: 24.3 M shares

Repros Therapeutics — Investor Presentation (September 2016) on 6ix